Dr. Yongbin Liu specializes in Pharmaceutical Science, with a particular focus on drug discovery and vaccine development. His academic journey began with a B.S. degree from the School of Pharmaceutical Science at Central South University (CSU). His enthusiasm for research led him to pursue a Ph.D. at the Institute of Clinical Pharmacology within Xiangya Hospital, also affiliated with CSU.

Following the completion of his doctoral studies, Dr. Liu joined the Department of Nanomedicine at the Houston Methodist Research Institute as a postdoctoral research fellow. In this role, he expanded his expertise to encompass nanotechnology-enabled drug delivery and cancer immunotherapy. His multidisciplinary research integrates medicinal chemistry, pharmaceutical sciences, and tumor immunology to develop innovative therapeutic strategies, with particular emphasis on overcoming drug resistance and enhancing anti-tumor immune responses.

In 2023, Dr. Liu was awarded the prestigious Postdoctoral Fellowship in Drug Discovery by The Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. His research has also led to multiple patent applications in the United States and internationally, underscoring his commitment to translating scientific discoveries into clinical applications.

Currently, Dr. Liu’s work focuses on the development of novel platinum-based therapeutics, nanoparticulate cancer vaccines, and targeted drug delivery systems. His overarching vision is to advance drug discovery methodologies and transform the treatment landscape for cancer and other diseases. With a passion for innovation and an unwavering determination to address unmet medical needs, Dr. Liu strives to provide hope and improve outcomes for patients worldwide.

Dr. Liu’s research spans medicinal chemistry, nanomedicine, and immunology, with applications in various diseases. His key interests include:

• Platinum-based therapeutics – Designing and developing next-generation platinum drugs and polymer–platinum conjugates to overcome drug resistance in cancers such as ovarian, breast, and colorectal cancer.

• Nanoparticulate vaccines – Engineering polymer-based nanoparticle platforms for the delivery of antigens and adjuvants to induce strong and durable immune responses against cancers, infectious diseases, and other conditions.

• Targeted drug delivery systems – Conjugating tissue-specific ligands and immunomodulatory agents to nanocarriers for precise delivery to diseased tissues and relevant immune cell populations.

• Immune microenvironment modulation – Investigating how therapeutic interventions reshape immune landscapes, with a focus on macrophage polarization, T cell activation, and resolution of chronic inflammation.

• Translational drug discovery – Advancing laboratory innovations into preclinical and clinical development to create patentable, clinically viable therapeutic platforms.

Through this work, Dr. Liu aims to integrate drug discovery and delivery technologies to address urgent unmet medical needs, ultimately improving health outcomes for patients worldwide.

Email: [email protected]